Trial · NCT02584634
Results by group172
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 172
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | Group A: Avelumab + Crizotinib | 5 | Participants | ||
| Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b | Group B: Avelumab + Lorlatinib | 2 | Participants | ||
| Percentage of Participants With Objective Response (OR): Phase 2 | Group A: Avelumab + Crizotinib | 25.0 | 95% Confidence Interval 5.5 to 57.2 | Percentage of participants | |
| Percentage of Participants With Objective Response (OR): Phase 2 | Group B: Avelumab + Lorlatinib | 51.6 | 95% Confidence Interval 33.1 to 69.8 | Percentage of participants | |
| Percentage of Participants With CR for Group B: Phase 2 | Group B: Avelumab + Lorlatinib | 3.2 | Percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with TEAEs | 12 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with TEAEs | 30 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with Grade >= 3 TEAEs | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with Grade >= 3 TEAEs | 23 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with treatment-related TEAEs | 12 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with treatment-related TEAEs | 28 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with Grade >= 3 treatment-related TEAEs | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with Grade >= 3 treatment-related TEAEs | 16 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with SAEs | 5 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with SAEs | 21 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with treatment-related SAEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with treatment-related SAEs | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with TEAEs leading to discontinuation of avelumab | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group B: Avelumab + Lorlatinib | Participants with TEAEs leading to discontinuation of avelumab | 10 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Group A: Avelumab + Crizotinib | Participants with TEAEs leading to discontinuation of crizotinib | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02584634/results